Khoo, 180 patient molnupiravir early treatment RCT: 89% lower hospitalization [p=0.12] and 23% improved viral clearance [p=0.07] https://c19p.org/khoo2
copied to clipboard
A Randomised-Controlled Phase 2 trial of Molnupiravir in Unvaccinated and Vaccinated Individuals with Early SARS-CoV-2
RCT 90 molnupiravir and 90 placebo patients, showing faster viral clearance with treatment, not reaching the pre-defined threshold for superiority and recommendation as a candidate for large scale evaluation. The supplementary figures and tables mentioned are not currently available.Concerns have been raised that the mutagenic mechanism of action may create dangerous variants or cause cancer [Hadj Hassine, Swanstrom].
|
risk of oxygen therapy, 66.7% lower, RR 0.33, p = 1.00, treatment 0 of 90 (0.0%), control 1 of 90 (1.1%), NNT 90, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
|
|
risk of hospitalization, 88.9% lower, RR 0.11, p = 0.12, treatment 0 of 90 (0.0%), control 4 of 90 (4.4%), NNT 22, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
|
|
risk of no viral clearance, 23.1% lower, HR 0.77, p = 0.07, treatment 90, control 90, primary outcome.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Khoo et al., 7/24/2022, Double Blind Randomized Controlled Trial, placebo-controlled, United Kingdom, preprint, 36 authors, study period 8 September, 2020 - 16 March, 2022, average treatment delay 3.3 days, trial NCT04746183 (history) (AGILE CST-2).
Contact:
khoo@liverpool.ac.uk.
Please send us corrections, updates, or comments. Vaccines and
treatments are both valuable and complementary. All practical, effective, and
safe means should be used. No treatment, vaccine, or intervention is 100%
available and effective for all current and future variants. Denying the
efficacy of any method increases mortality, morbidity, collateral damage, and
the risk of endemic status. We do not provide medical advice. Before taking
any medication, consult a qualified physician who can provide personalized
advice and details of risks and benefits based on your medical history and
situation. FLCCC and WCH
provide treatment protocols.